Industry Spotlight

Another anti-PD-L1 cancer therapy emerging

7 March 2017 via Biotech Dispatch: A major development for patients with urothelial carcinoma with Merck and Pfizer announcing they have submitted avelumab to the FDA.

It has priority review status by the FDA, which could reduce the review time to six months, having already been granted priority review status for the treatment of patients with metastatic Merkel cell carcinoma.

The new submission seeks approval for avelumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with disease progression on or after platinum-based therapy.

Read more in Biotech Dispatch.

Back